Gates Foundation backs CureVac with $52m, Hopp invests $24m
This article was originally published in Scrip
The Bill & Melinda Gates Foundation made its largest-ever equity investment in a biotechnology company when it committed $52m to the continued development of Tubingen, Germany-based CureVac's novel vaccines and construction of manufacturing facilities.
You may also be interested in...
If in five years' time the newly launched CEPI coalition successfully produces DNA and RNA-based vaccines for use against future epidemics, then the high-profile Davos forum will really have something to crow about.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.